Industry News

Friday, November 20, 2009

• Biogen shareholders: CEO pay 'inconsistent' with poor stock performance
• Second license deal with Amgen to bring ImmunoGen another $35M

Thursday, November 19, 2009

• German biotech Caprotec opens Burlington subsidiary
• Genzyme halts kidney treatment development
• ACT seeks FDA OK for stem cell study to treat blindness
• Biotech startup Ligon Discovery attracts $1M in VC funds

Wednesday, November 18, 2009

• Knome targets researchers with new genomic service

Tuesday, November 17, 2009

• Clinical Data names scientific board
• Advanced BioHealing begins skin substitute trial
• Alkermes moves alcohol dependency drug candidate to Phase 2 study

Monday, November 16, 2009

• FDA rejects Genzyme’s Pompe disease drug again
• ACT closes $15M private placement

Friday, November 13, 2009

• Five Genzyme drugs contaminated; stock plummets
• Biotech, pharma foresee higher costs from House health reform bill

Thursday, November 12, 2009

• Cequent files first IND application
• Novelos closes $9M private placement

Wednesday, November 11, 2009

• Vertex exchanges notes for company stock

Tuesday, November 10, 2009

• Helicos ends acquisition talks
• BioTrove poised for acquisition, new spin-out
• BioVex boosts Series F to $70M to move cancer treatment forward

Monday, November 9, 2009

• GTC Biotherapeutics execs land retention pay amid layoffs

Wednesday, November 4, 2009

• Job cuts help CombinatoRx narrow Q3 loss

Tuesday, November 3, 2009

• Genzyme manufacturing plant gets EU OK

Monday, November 2, 2009

• Seaside launches trial for autism treatment
• RNAi startup Cequent raises $3.4M
• GTC Biotherapeutics pulls in $10M from shareholder
• Pulmatrix lands $32M in multiple fundings

Friday, October 30, 2009

• Third Rock rests VC hopes in rare genetic disease treatments

Thursday, October 29, 2009

• Celldex cancer drug candidate returns positive news
• Virdante Pharmaceuticals boosts first round to $47M

Wednesday, October 28, 2009

• Stryker Biotech indicted in deceit scheme
• Excelimmune wins SBIR grant

Tuesday, October 27, 2009

• Aiko opioid painkiller returns positive trial results

Monday, October 26, 2009

• Positive results for Antigenics' brain cancer therapy
• Cephalon pays $30M for option to buy BioAssets

Friday, October 23, 2009

• Biogen shares tumble on more MS drug-linked infections
• Molecular Insight signs global cancer therapy deal
• Biocell Center opens amniotic stem cell bank in Medford
• Nuclea wraps up $3.4 million funding

Wednesday, October 21, 2009

• Genzyme Q3 net income plummets amid plant shutdown woes
• Genzyme moves oral Gaucher disease drug to Phase 3 trials

Tuesday, October 20, 2009

• Biogen Q3 net income, revenue increase
• Synageva closes newly increased $45M investment

From the Print Edition

• How I See It: Success in a biotech launch starts with a great team